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Abstract
Background: Ataxia telangiectasia (A-T) is a neurodegenerative disease that leads to mitochondrial dysfunction and
oxidative stress. Insulin resistance (IR), type 2 diabetes and the risk for development of cardiovascular disease was
recently associated as an extended phenotype of the disease. We aimed to assess IR; liver involvement; carotid
intima-media thickness (cIMT) and metabolic alterations associated to cardiovascular risk in A-T patients, and relate
them with age.
Results: Glucose metabolism alterations were found in 54.6% of the patients. Hepatic steatosis was diagnosed in
11/17 (64.7%) A-T patients. AST/ALT ratio > 1 was observed in 10/17 (58.8%). A strong positive correlation was
observed between insulin sum concentrations with ALT (r = 0.782, p < 0.004) and age (r = 0.818, p = 0.002).
Dyslipidemia was observed in 55.5% of the patients. The apolipoprotein (Apo-B)/ApoA-I ratio (r = 0.619; p < 0.01),
LDL/HDL-c (r = 0.490; p < 0.05) and the Apo-B levels (r = 0.545; p < 0.05) were positively correlated to cIMT.
Conclusions: Metabolic disorders implicated in cardiovascular and liver diseases are frequently observed in
adolescent A-T patients and those tend to get worse as they become older. Therefore, nutritional intervention and
the use of drugs may be necessary.
Keywords: Ataxia Telangiectasia, Atherosclerosis, Carotid Intima-media thickness, Insulin resistance, Fatty liver
disease, Dyslipidemia, Nutritional status, Diabetes
Background
Clinical and biochemical alterations, such as reduction
of lean mass, premature aging, insulin resistance (IR),
type 2 diabetes, and risk of developing cardiovascular
(CV) disease [1] have been recently added to the classic
phenotype of ataxia telangiectasia (A-T).
The disease is caused by mutations in the ataxia-
telangiectasia mutated (ATM) gene [2] and causes reduc-
tion in antioxidant cell capacity and constant oxidative
stress that are related to the development of chronic
morbidities [3, 4].
ATM-deficient mice showed glucose intolerance, IR,
and impaired insulin secretion whose mechanisms are
not fully known [5, 6]. A recent study showed high
blood glucose and low insulin sensitivity in patients with
A-T compared to healthy controls [7].
Literature is still scarce regarding the liver changes ob-
served in A-T patients. A mouse model study empha-
sized the important role of the ATM pathway in liver fat
accumulation and has associated its activation to
steatohepatitis-apoptosis and fibrosis – both considered
important findings for the progression of nonalcoholic
fatty liver disease (NAFLD) [8].
Regarding the CV risk, an ATM study with apolipopro-
tein (Apo) E-deficient mice has described the emergence
of atherosclerotic lesions with accelerated progression in
association with IR and glucose intolerance [9].
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Furthermore, it was found that ATM deficiency resulted
in an increased c-jun N terminal kinase (JNK) activity re-
lated to metabolic syndrome [10], failure in the regulation
of the Nuclear Factor kappa B (NF-kB) expression, in-
creased production of free radicals, and reduction of oxi-
dative phosphorylation, leading to changes in lipid and
glucose metabolism [11].
The CV risk can be assessed by biochemical methods
and non-invasive imaging techniques, such as carotid
intima-media thickness (cIMT) by ultrasonography (US).
A previous study conducted by our group has identified
significant changes in triglyceride levels (TG), choles-
terol fractions of Non-HDL-c (NHDL-c), and in the rela-
tionship between CT/HDL-c and LDL-c/HDL-c in
patients with A-T [12].
Given the lack of studies on the metabolic changes ob-
served in A-T involved in the risk of developing chronic
diseases, the aim of this study was to assess IR; liver in-
volvement; carotid intima-media thickness (cIMT) and
metabolic alterations associated to cardiovascular risk in
A-T patients, and relate them with age.
Methods
In a cross-sectional controlled study, we evaluated 18 A-T
patients of both genders, between 5 and 25 years of age,
who were diagnosed with A-T according to the criteria of
the European Society for Immunodeficiencies (ESID) [13].
The control group was composed by 17 healthy individ-
uals matched in age, gender and pubertal stage; it was
used to compare biochemical markers related to cardio-
vascular risk and food intake. The study was approved by
the Research Ethics Committee from the Federal Univer-
sity of São Paulo (UNIFESP). Patients and controls with
acute infection at the time of collection were exclude, as
well as those using oral corticosteroids or hypoglycemic
agents in the 3 months prior to collection.
Anthropometric evaluation and food intake
The anthropometric evaluation included the measure-
ment of weight, height, mid-upper arm circumference
(MUAC) and skinfold thickness (tricipital, subscapular,
bicipital, and sacroiliac). The patients who were unable
to stand upright were weighed in their parent’s arms and
their recumbent height was measured on a firm, flat sur-
face using an inextensible tape that was graduated in
millimeters.
In order to classify nutritional status, body mass index
to age z-score (ZBMI) for children/adolescents and body
mass index (BMI) for adults were calculated. The sum of
skinfold thickness and MUAC was used to estimate body
composition [14–17]. Pubertal stage was evaluated ac-
cording to Marshall and Tanner [18].
The assessment of food intake was performed using a
24 h dietary recall (R24hs). The calculation of nutrients in
the diet was performed by use of the software Diet Win®
and was analyzed according to Dietary Reference Intakes
(DRIs) [19]. None of A-T patients had feeding tubes.
CV risk assessment
The lipid profile [triglycerides (TG), total cholesterol
(TC), HDL-c, and LDL-c] was measured with
enzymatic-colorimetric tests [20, 21]. The non-HDL
cholesterol (NHDL-c) values were obtained by subtract-
ing the HDL-c values from the TC values [21, 22]. Apo
A-I, Apo B, small-dense LDL-c particles (sdLDL), oxi-
dized LDL (LDL-ox) and lipoprotein (a) [Lp(a)] were
assessed by immune turbid metric assays (ELISAPRO®
Human Mabitech Kit).
The assessment of the carotid intima media thickness
(cIMT) was performed only in A-T patients in a blinded
fashion by a single examiner who used Doppler Ultra-
sonography (Medison equipment, Accuvix V10 model
with linear transducer of high frequency of 6 - 12 MHz).
A short length no longer than 0,5 cm of the distal com-
mon carotid artery was chosen, at a distance of 1 cm
from the bulb, in which three equidistant measurements
of cIMT were taken from the far wall and mean values
were considered [23].
Liver involvement
The biochemical markers were collected for hepatic
evaluation such as alanine aminotransferase (ALT) and
aspartate aminotransferase (AST). AST/ALT ratio > 1
was considered as indicative of liver fibrosis. Hepatic
steatosis was evaluated by ultrasonography in a blinded
fashion by a single examiner [24]. Liver involvement was
considered when the A-T patients presented hepatic
steatosis plus ALT higher than 40 U/L (reference value)
or only ALT higher than 40 U/L.
Assessment of IR
Standard 75-g oral glucose tolerance test (OGTT): glu-
cose and insulin levels were measured at 0, 30, 60, 90,
and 120 min. Glucose intolerance was considered when,
at 120 min, glycaemia was ≥140 mg/dL and <200 mg/dL
and IR was considered when the sum of the five insulin
levels measured were >300mUI/mL [25].
Statistical analysis
The statistical package SPSS 24.0 was used for the ana-
lysis. Continuous variables were tested for normality. For
comparisons between nonparametric variables, the
Mann-Whitney or Kruskal-Wallis test was used and, for
the parametric variables, the t-Student or ANOVA test
was used. The Chi-square test or Fisher’s exact test was
used to analyze the association between qualitative vari-
ables. We used Pearson’s and Spearman’s correlation
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coefficient for comparing the analyzed parameters. A
significance level of 5% (p < 0.05) was adopted.
Results
The mean age of A-T patients was 13.9 years old, with
15 (83.3%) males and 9 (50%) pre-pubertal. Eleven out
of 18 (61.1%) received regular immunoglobulin infusion.
The classification of nutritional status by BMI and
MUAC are in Table 1 and more than 50% of the patients
had dyslipidemia. Glucose metabolism alterations were
found in 6/11 (54.6%) patients. One patient was diag-
nosed with diabetes mellitus (Table 1).
Hepatic steatosis was diagnosed in 11/17 (64.7%) A-T
patients. AST/ALT ratio > 1 was observed in 10/17
(58.8%) (Table 1). The mean ALT and AST levels, and
AST/ALT ratio was 37.7 ± 27.1 U/L, 34.3 ± 11.6 U/L e
1.3 ± 0.7 U/L, respectively. It is also important to note
those patients with elevated ALT levels, these levels
remained elevated at 6-months clinical follow up (data
not shown). Table 2 shows individual ALT and AST
values for A-T patients.
Malnutrition and overweight were observed in 6/18
(33.3%) and 1/18 (5.5%) A-T patients, respectively. In the
control group, malnutrition and overweight were verified
in 1/17 (5.9%) and 7/17 (41.2%), respectively. Despite the
fact, that the mean BMI (17.3 ± 4.0 kg/m2 vs
21.3 ± 4.8 kg/m2; p = 0.010) was lower in A-T patients we
observed in this group in comparison to controls higher
levels of Apo B (274.1 ± 184.4 mg/mL vs 167.0 ± 46.0 mg/
mL; p = 0.027); ApoB/Apo A1 ratio (2.1 ± 1.4 vs 1.2 ± 0.3;
p = 0.018) and Lp(a) (182.8 (31.2;585.8) pg/mL vs 31.2
(31.2;334.9) pg/mL; p < 0.001) suggestive ofa more athero-
genic lipid profile (Table 3).
The mean cIMT of A-T patients was 0.42 mm (range:
0.20 and 0.50). The ApoB/ApoA-I ratio (r = 0.619;
p < 0.01), LDL/HDL-c (r = 0.490; p < 0.05), and the
ApoB values (r = 0.545; p < 0.05) were positively corre-
lated to cIMT.
Figure 1 shows the correlation between insulin sum
concentrations of the OGTT, in A-T patients, with ALT
(r = 0.782, p < 0.004) and age (r = 0.818, p = 0.002). We
observed a strong positive correlation between insulin
sum concentrations with ALT and age. The strongest
was with age.
Figure 2 shows that patients who presented with liver
involvement had higher sum of insulin levels [590.7 μU/
mL (19.1;153.3); p = 0.047] and older age (20.2 ± 4.5 years
of age; p = 0.001) as compared to those patients who
had only hepatic steatosis [86.2 μU/mL (19.1;152.3)
/10 ± 5.2 years of age] and those without liver involve-
ment [148.1μU/mL (63.1;415.9) /9.9 ± 2.1 years of age].
There were no differences regarding energy and
macronutrients intake between A-T group and control
group (Table 4).
Discussion
This study emphasizes the CV, diabetes, and liver disease
risks in A-T patients evidenced by atherogenic lipid pro-
file [higher values of Lp(a) and ApoB/Apo A-I], IR, and
presence of hepatic steatosis in 64.7% of the patients.
Moreover, it was found that the increase in age was a
risk factor for insulin resistance and liver involvement.
The ATM activity seems to be implicated in the gly-
cemic response to metformin in type 2 diabetes [26] and
in CV disease [27].
Over time, patients with A-T develop a catabolic con-
dition associated with decline in BMI, chronic lung dis-
ease, worsening of hepatic function and glucose
metabolism [28], as observed in our study. A recent
retrospective cohort study of 55 patients with A-T found
endocrine abnormalities, such as diabetes, dyslipidemia,
and changes in liver function in two adults [29].
Table 1 Characterization of patients with A-T
Variable N (%)
Age (n = 18) 5–15 years 12 (66.6%)
16–25 years 6 (33.3%)
Nutritional status (n = 18) Malnutrition 6 (33.3%)
Normal body mass index 11 (61.1%)
Overweight 1 (5.5%)
Fat mass (n = 18) Low 2 (11.1%)
Adequate 9 (50.0%)
High 7 (38.9%)
Mid-upper arm
muscle circumference
(n = 18)
Low 10 (55.5%)
Adequate 8 (44.4%)
Lipid profile (n = 18) High total cholesterol 10 (55.5%)
High LDL-c 10 (55.5%)
High triglyceride 8 (44.4%)
Low HDL-c 10 (55.5%)
High NHDL-c 11 (61.1%)
Diabetes mellitus
(n = 18)
>200 mg/dL 1 (5.5%)
Oral Glucose
Tolerance Test (n = 11)
Normal 5 (45.4%)
Glucose intolerance 1 (9.1%)
Insulin resistance 4 (36.4%)
Glucose intolerance and
Insulin resistance
1 (9.1%)
ALT (n = 17) > 40 U/L 7 (41.2%)
AST/ALT (n = 17) > 1 10 (58.8%)
Hepatic steatosis (n = 17) No 6 (35.3%)
Mild 7 (41.2%)
Moderate 4 (23.5%)
Liver involvement (n = 17) 7 (41.2%)
N (%)
Legend: LDL-c low density lipoprotein cholesterol, HDL-c high density
lipoprotein cholesterol, NHDL-c Non-HDL-c, ALT alanine aminotransferase, and
AST/ALT aspartate aminotransferase/alanine aminotransferase
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It is known that IR and atherosclerosis are risk factors
for developing CV disease, with oxidative stress being
related to both complications [30, 31]. IR is also impli-
cated as a key factor in the pathogenesis of steatohepati-
tis [32], with a positive association of oxidative stress
and the severity of liver disease in humans [33]. The
deficiency of ATM protein is presented as an important
link between the metabolic changes observed in A-T
patients.
A recent study, such as observed by us, has found
higher glycemia and lower insulin sensitivity in patients
with A-T [9]. Some hypotheses can be raised to explain
this finding, such as the participation of the ATM in the
insulin signaling pathway via phosphorylation of eIF-4E
(eukaryotic translation initiation factor 4E) [34] and the
regulation exerted by the serine-threonine kinase protein
(AKt) or protein kinase B (PKB) activity, which regulates
glucose-transporter 4 (GLUT4) translocation by insulin
in skeletal muscle and adipose tissue [35].
In our study, abnormalities in glucose metabolism
were observed in all pubertal patients who under-
went the test. This finding strongly recommends the
importance of performing the OGTT in all A-T pu-
bertal patients aimed an early detection of glucose
metabolism disorders.
Inflammation is an important factor for the develop-
ment of obesity-induced IR and it involves tissue im-
mune cells, including phagocytes, lymphocytes, and
cytokines [36]. Only one of our patients was obese,
showing that this condition is not the cause of IR. Re-
cently, it was demonstrated that the neutrophils from A-
T patients produce significantly more cytokines and live
longer compared to those from controls, suggesting that
innate immune dysfunction may drive inflammation in
A-T patients [37]. In a cross-sectional study, the geomet-
ric mean of interleukin (IL)-8 level was significantly
higher in A-T patients compared with non-A-T
Table 2 Alanine aminotransferase and aspartate
aminotransferase values of the A-T group
A-T Group
(n = 17)
Aspartate aminotransferase
(U/L)
Alanine aminotransferase
(U/L)
1 25 10
2 21 14
3 35 28.1
4 51 99.8
5 27 12.2
6 24 23.5
7 34 22.3
8 34 18.6
9 66 49
10 19 50
11 27 17
12 36 13
13 30 59
14 41 50
15 40 90.8
16 31 31.8
17 43 52.7
Table 3 Comparison of the variables in A-T group and control group
Variable A-T Group (n = 18) Controls (n = 17) p Value
Total cholesterol mg/dL 177.4 ± 33.3 170.0 ± 25.4 0.448a
LDL-c mg/dL 115.4 ± 32.3 107.6 ± 22.3 0.412a
HDL-c mg/dL 43.5 ± 10.8 45.2 ± 8.1 0.596a
Triglycerides mg/dL 94.1 ± 47.2 91.7 ± 45.8 0.880a
Non-HDL-cholesterol mg/dL 134.2 ± 35.7 124.8 ± 25.6 0.377a
Total cholesterol/HDL-c mg/dL 4.3 ± 1.4 3.9 ± 0.9 0.265a
LDL/HDL mg/dL 2.8 ± 1.1 2.5 ± 0.8 0.272a
Apo A-I mg/mL 130.8 ± 27.2 138.8 ± 19.8 0.330a
Apo B mg/mL 274.1 ± 184.4 167.0 ± 46.0 0.027a
Apo B/Apo AI mg/mL 2.1 ± 1.4 1.2 ± 0.3 0.018a
LDL/ApoB mg/mL 0.56 ± 0.42 0.67 ± 0.15 0.327a
Lp(a) pg/mL 182.8 (31.2;585.8) 31.2 (31.2;334.9) 0.001b
LDLox pg/mL 2610.0 ± 985.0 2338.4 ± 982.6 0.533a
sdLDL-c mmol/L 3.3 ± 0.9 3.2 ± 0.9 0.641a
aSignificance level of the t-Student test.b Significance level of the Mann-Whitney test
Legend: LDL-c low density lipoprotein cholesterol, HDL-c high density lipoprotein cholesterol, TC total cholesterol, Apo AI apolipoprotein A, Apo B apolipoprotein B,
LDLox oxidized LDL and Lp(a) [lipoprotein (a)]
The bold text means the p-value of satistical tests (t-Student1 or Mann-Witney2 are less than p< 0,05 (there was statistical significance)
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(p < .0001) [38]. McGrath-Morrow et al. [39] found that
approximately 80% of the A-T patients had elevated
levels of serumIL-6 and 23.6% having increased levels of
IL-6 and IL-8. Furthermore, serum IL-6 levels were cor-
related with lower lung function.
There are evidences that apolipoproteins are better
predictors of CV risk compared to the classic lipid pro-
file [40] and, the Apo B/Apo A-I ratio seems to be a bet-
ter CV risk predictor [41] that was abnormal in our
patients in addiction to the cIMT alteration.
One third of our A-T patients presented undernutri-
tion and 55.5% of them had a compromised body mass.
Only 11.1% of the patients had deficit of body fat, which
indicates that malnutrition in these patients is associated
with reduced lean mass. It is also important to note that
of the six patients with glucose metabolism disorders
and one with diabetes, five of them had compromised
lean mass and six had high NHDL-c values, which rein-
forces risk factors for developing CV disease dependent
on ATM activity (data not shown).
A retrospective cohort study of 53 patients with A-T
found liver enzyme abnormalities in 43.4% (23/53) and
the presence of steatosis by US in 39% (9/23). Liver bi-
opsy was performed in two patients and showed mild to
moderate steatosis in both of them and fibrosis in one of
them, supporting our results [42]. Recently, nonalcoholic
steatohepatitis without ATM protein in the nucleus of
the hepatocytes was showed in a liver biopsy in one A-T
patient [43]. One of our patients not included in this
study, passed away at 30 years of age with liver cirrhosis,
suggesting that this morbidity could affect older A-T pa-
tients. The small sample size of this study is a limitation,
Fig. 1 Correlation between insulin sum concentrations of the oral glucose tolerance test (n = 11) in patients with A-T with ALT (n = 17) and age
(n = 18). *Significance level of Spearman correlation test
Fig. 2 Insulin sum concentrations of the oral glucose tolerance test in A-T patients (n = 11) without liver involvement, with hepatic steatosis only
and with liver involvement; association with age. * Significance level of the test: ANOVA for patients without liver involvement, only hepatic
steatosis and with liver involvement vs age (years), * p = 0.001. Kruskal-Wallis test for patients without liver involvement, only hepatic steatosis
and with liver involvement vs insulin sum concentrations (μU/mL), * p = 0.047
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but for the first time in the literature, we described the
association between IR and liver involvement which
leads us to recommend the evaluation of glucose metab-
olism, liver function and US in A-T adolescents. Further
studies are necessary to clarify the role of ATM protein
in those mechanisms.
Conclusions
Metabolic disorders implicated in cardiovascular and liver
involvement are observed in adolescent A-T patients and
those tend to get worse as they become older. Drugs usu-
ally employed in diabetes, dyslipidemia and metabolic syn-
drome have unconvincing results in A-T patients, stressing
the need for new treatment alternatives. Therefore nutri-
tional intervention encouraging the use of antioxidants nu-
trients and new drugs, taking account the pathophysiology
of the disease and side effects may be necessary.
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